My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Actas Urológicas Españolas
Print version ISSN 0210-4806
Abstract
GUINOT, J.L. et al. Results of 125-Iodine seed implant with preplanning system in 250 patients with prostate cancer. Actas Urol Esp [online]. 2011, vol.35, n.6, pp.339-344. ISSN 0210-4806.
Introduction: We review the experience with prostate carcinoma patients treated with permanent implants of 125-I seeds and the outcome eight years after the beginning of this technique. Material and methods: From 2002 to 2007 we have performed 250 implants with LDR brachytherapy with RapidStrand® and preplanning system. Mean age was 68 (49-78). Mean PSA was 7.32 (2.31 - 14.6). T1-T2a was the stage in 98%, and Gleason < 6 in 96%. Low risk cases were 81% and intermediate risk 19% (ten of them received 46Gy EBRT). Hormonal treatment was used in 42%. Results: With a mean follow-up of 48 months, 14 patients (5.7%) showed biochemical failure (BF). Eleven patients (4.5%) with theoretical BF were observed and PSA decreased without treatment. Actuarial PSA relapse-free survival at 5 years was 91%, (92% low risk, 86% intermediate cases), and 92% vs 81% with PSA <10 vs >10 (p<0.05). Rectum complications were G2 in 0.6%. A urinary catheter was necessary in 6.5%. Sexual function was conserved in 60%. Mean V100 was 89% and D90 143Gy. Conclusion: The outcome of patients with low risk prostate carcinoma treated with I-125 seed is very good with very low complications rate. Cases with PSA bounces should be controlled before starting a salvage treatment.
Keywords : Prostate; 125-I seeds; Brachytherapy; Real-time.